Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04486118 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Centrally Acting ACE Inhibition in SLE

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Jun 1, 2025 to Jun 3, 2025 Completion date: Nov 1, 2025 to Mar 1, 2026v11 Show 1 more changeShow less
    • Completion date: Nov 1, 2025 to Mar 1, 2026
  2. Trial status: Recruiting to Active, Not Recruiting Site details revised at 7 of 7 sitesv10 Show 1 more changeShow less
    • Site details revised at 7 of 7 sites
  3. Study sites: 6 to 7v9
  4. Primary completion date: Jan 1, 2024 to Jun 1, 2025 Completion date: Nov 1, 2024 to Nov 1, 2025v8 Show 1 more changeShow less
    • Completion date: Nov 1, 2024 to Nov 1, 2025
  5. Study sites: 7 to 6 Eligibility criteria shortened, about 2 wordsv7 Show 1 more changeShow less
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Oct 1, 2023 to Jan 1, 2024 Completion date: Jul 1, 2024 to Nov 1, 2024v6 Show 1 more changeShow less
    • Completion date: Jul 1, 2024 to Nov 1, 2024
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 7v5 Show 1 more changeShow less
    • Study sites: 0 to 7
  3. Primary completion date: Jun 1, 2022 to Oct 1, 2023 Start date: May 1, 2021 to Oct 1, 2021 · Completion date: Apr 1, 2023 to Jul 1, 2024v4 Show 2 more changesShow less
    • Start date: May 1, 2021 to Oct 1, 2021
    • Completion date: Apr 1, 2023 to Jul 1, 2024
  4. Start date: Feb 1, 2021 to May 1, 2021 Primary completion date: Apr 1, 2022 to Jun 1, 2022v3 Show 1 more changeShow less
    • Primary completion date: Apr 1, 2022 to Jun 1, 2022
  5. Start date: Sep 1, 2020 to Feb 1, 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Northwell Health
133 trials monitored
See 10 trials at risk
Lupus (SLE)
651 trials monitored
See 25 trials at risk
SLE is a chronic autoimmune disease that often involves multiple systems and organs of the body. An autoimmune disease is one which your immune system attacks the cells and tissues in different parts of the body. SLE is characterized by inflammation that leads to tissue damage in many different organ systems. Lupus can cause fever, joint pains, rashes, and other symptoms. It can also affect organs such as the skin, the muscles, the kidneys, the heart, the lungs, the blood and the brain. The exact cause of SLE is not known. Problems with memory and concentration are common in lupus; these problems are called cognitive problems. Cognitive problems can be caused by things like depression, fatigue, medication and infections. However, previous studies that have been done in animal models of lupus and in lupus patients suggest that inflammation due to lupus can affect the brain directly. This research study is being done to test the effects of centrally-acting ACE inhibitor, named lisinopril, on resting metabolism in the brain and on cognitive function. The investigators will see if Lisinopril will decrease resting metabolism in the brain and improve cognitive function (memory and concentration) compared to a non-centrally acting ACE inhibitor called benazepril.
Trial Details
NCT Number NCT04486118
Lead Sponsor Northwell Health
Collaborators: Lupus Research Alliance
Conditions Systemic Lupus Erythematosus
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov